AACR 2024 | Copanlisib and olaparib in PIK3CA hotspot, PTEN and DDR mutant tumors

Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses findings from the Phase Ib NCI10217 trial (NCT03842228) of combination of the biomarker-driven tumor-agnostic copanlisib, a pan-PI3K inhibitor, and olaparib, a PARP inhibitor, in tumors with PI3K/AKT or DDR mutations. Partial responses were recorded and the recommended Phase II dose was also determined. The combination demonstrated safety and efficacy in advanced cancers with PIK3CA hotspot, PTEN, and/or DDR mutations. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.